180 related articles for article (PubMed ID: 33235471)
21. Non-invasive Molecular Detection of Minimal Residual Disease in Papillary Thyroid Cancer Patients.
Almubarak H; Qassem E; Alghofaili L; Alzahrani AS; Karakas B
Front Oncol; 2019; 9():1510. PubMed ID: 31998653
[No Abstract] [Full Text] [Related]
22. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
[TBL] [Abstract][Full Text] [Related]
23. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
24. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
25.
Jensen LH; Olesen R; Petersen LN; Boysen AK; Andersen RF; Lindebjerg J; Nottelmann L; Thomsen CEB; Havelund BM; Jakobsen A; Hansen TF
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31731482
[TBL] [Abstract][Full Text] [Related]
26. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Tan L; Tran B; Tie J; Markman B; Ananda S; Tebbutt NC; Michael M; Link E; Wong SQ; Chandrashekar S; Guinto J; Ritchie D; Koldej R; Solomon BJ; McArthur GA; Hicks RJ; Gibbs P; Dawson SJ; Desai J
Clin Cancer Res; 2023 Mar; 29(6):1017-1030. PubMed ID: 36638198
[TBL] [Abstract][Full Text] [Related]
27. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.
Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M
Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541
[TBL] [Abstract][Full Text] [Related]
28. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
Calapre L; Warburton L; Millward M; Gray ES
BMC Cancer; 2019 Nov; 19(1):1109. PubMed ID: 31727009
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of BRAF
Tang H; Kong Y; Si L; Cui C; Sheng X; Chi Z; Dai J; Yu S; Ma M; Wu X; Yu J; Xu T; Yu H; Yan J; Guo J
Oncol Lett; 2018 Feb; 15(2):1839-1844. PubMed ID: 29434880
[TBL] [Abstract][Full Text] [Related]
31. Three-target treatment combined with surgery for BRAF V600E-mutant colon cancer with peritoneal metastasis: a case report.
Li HX; Zhang XL; Zhang JQ; Cai M; Li SW
J Gastrointest Oncol; 2022 Oct; 13(5):2647-2653. PubMed ID: 36388686
[TBL] [Abstract][Full Text] [Related]
32. Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer.
Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Tamura F; Nagashima H; Fujikawa K; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Front Oncol; 2023; 13():1203296. PubMed ID: 37434969
[TBL] [Abstract][Full Text] [Related]
33. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
35. KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report.
Xiong Q; Zeng Z; Yang Y; Wang Y; Xu Y; Zhou Y; Liu J; Zhang Z; Qiu M; Zhu Q
Front Oncol; 2022; 12():872630. PubMed ID: 35734602
[TBL] [Abstract][Full Text] [Related]
36. BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report.
Peker YS; Can MF; Ozerhan IH; Yagci G; Zeybek N; Kavakli K; Gurkok S; Gozubuyuk A; Genc O; Erdem G; Ozet A; Gerek M; Peker Y
Case Rep Surg; 2018; 2018():8782328. PubMed ID: 29850361
[TBL] [Abstract][Full Text] [Related]
37.
Kono H; Yamanaka T; Nishihara Y; Tomizawa K; Kizawa R; Yamaguchi T; Tanabe Y; Matoba S; Kuroyanagi H; Suyama K; Miura Y
Cancer Diagn Progn; 2023; 3(5):605-608. PubMed ID: 37671312
[TBL] [Abstract][Full Text] [Related]
38. BRAF
Gourdin G; Chotel L; de la Fouchardière C
Adv Ther; 2023 Aug; 40(8):3281-3290. PubMed ID: 37316651
[TBL] [Abstract][Full Text] [Related]
39. Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF
Cho SM; Esmail A; Abdelrahim M
Front Pharmacol; 2021; 12():795381. PubMed ID: 34975492
[TBL] [Abstract][Full Text] [Related]
40. Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA.
Ye LF; Huang ZY; Chen XX; Chen ZG; Wu SX; Ren C; Hu MT; Bao H; Jin Y; Wang F; Wang FH; Du ZM; Wu X; Ju HQ; Shao Y; Li YH; Xu RH; Wang DS
Drug Resist Updat; 2022 Dec; 65():100883. PubMed ID: 36202008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
